简
繁
EN
简
繁
EN
Home
Latest
Finance
IPO
ETF
Technology
Overseas
Research
HOME
·
Csop Tesla Daily (2x) Leveraged Product
Csop Tesla Daily (2x) Leveraged Product(07766.HK) Surges 6.18% in Morning Trading, NAV at HK$119.646
Tags:
Csop Tesla Daily (2x) Leveraged Product
07766.HK
ETF
2026-06-09
Csop Tesla Daily (2x) Leveraged Product(07766.HK) falls 0.73% intraday, NAV per unit at HK$140.808
Tags:
Csop Tesla Daily (2x) Leveraged Product
07766.HK
ETF
2026-05-28
Csop Tesla Daily (2x) Leveraged Product(07766.HK) Closed Down 8.43% at 126.500 HKD
Tags:
ETF
Csop Tesla Daily (2x) Leveraged Product
07766.HK
2026-05-18
Csop Tesla Daily (2x) Leveraged Product(07766.HK) rose 7.21% to HKD 126.400
Tags:
ETF
Csop Tesla Daily (2x) Leveraged Product
07766.HK
2026-05-08
Csop Tesla Daily (2x) Leveraged Product (07766.HK) Rises 16.69%, Quoted at HKD 118.15
Tags:
Csop Tesla Daily (2x) Leveraged Product
07766.HK
ETF
2026-04-16
Featured News
Finance
Marketingforce Management(02556.HK): Profit Forecast, Interim Revenue from AI Application Business Expected to Surge 112% to 134%
Finance
Hengrui Pharmaceuticals(01276.HK): Concentrated Solution for Injection HRS-8829 Receives Clinical Trial Approval Notice
Finance
MicroPort Scientific (00853.HK): Proposed Disposal of Controlling Stake in MicroPort Orthopedics (Shanghai) to Tinavi Medical
Finance
Renrui Human Resources(06919.HK): Non-executive Director Wang Xinjie Resigns; Gao Yunjie Appointed
Finance
Ubox Online (02429.HK): Full Circulation of H Shares Approved by HKEX
Finance
Chengdu Expressway (01785.HK): Signs Precast Concrete Component Procurement Contract for Chengdu-Wenjiang-Qionglai Expressway Expansion Project Worth Approximately RMB 234 Million
Finance
Prinx Chengshan (01809.HK): CEO Reshuffle – Che Baozhen Steps Down, Jiang Xizhou Appointed as President
Finance
Fameglow Holdings(03774.HK): Enters Technology Development Agreement with Sunseeker to Jointly Develop AI Anti-Aging Platform
Finance
Zhongtai Futures (01461.HK): Positive Profit Alert, Interim Net Profit Attributable to Parent Expected to Rise 190% to 210%
Finance
InnoCare Pharma Limited(09969.HK): Phase III Registrational Trial of Soficitinib (ICP-332) for Moderate-to-Severe Atopic Dermatitis Meets Primary Endpoint Successfully
Scan QR Code
Download App